These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evidence for polyreactive xenoreactive antibodies in the repertoire of human anti-swine antibodies: the 'next' humoral barrier to xenotransplantation? Gaca JG; Lee W; Aksoy O; Braedehoeft SJ; Gonzalez-Stawinski GV; Parker W; Davis RD Transpl Immunol; 2001 Oct; 9(1):19-27. PubMed ID: 11680568 [TBL] [Abstract][Full Text] [Related]
5. Xenoreactive natural antibodies in the world of natural antibodies: typical or unique? Parker W; Bruno D; Platt JL Transpl Immunol; 1995 Sep; 3(3):181-91. PubMed ID: 8581406 [TBL] [Abstract][Full Text] [Related]
6. Immunochemical properties of anti-Gal alpha 1-3Gal antibodies after sensitization with xenogeneic tissues. Yu PB; Parker W; Everett ML; Fox IJ; Platt JL J Clin Immunol; 1999 Mar; 19(2):116-26. PubMed ID: 10226886 [TBL] [Abstract][Full Text] [Related]
7. Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies. Yu PB; Holzknecht ZE; Bruno D; Parker W; Platt JL J Immunol; 1996 Dec; 157(11):5163-8. PubMed ID: 8943428 [TBL] [Abstract][Full Text] [Related]
8. The footprint of antibody bound to pig cells: evidence of complex surface topology. Everett ML; Lin SS; Worrell SS; Platt JL; Parker W Biochem Biophys Res Commun; 2003 Feb; 301(3):751-7. PubMed ID: 12565844 [TBL] [Abstract][Full Text] [Related]
10. Intracellular expression in pig cells of anti-alpha1,3galactosyltransferase single-chain FV antibodies reduces Gal alpha1,3Gal expression and inhibits cytotoxicity mediated by anti-Gal xenoantibodies. Vanhove B; Charreau B; Cassard A; Pourcel C; Soulillou JP Transplantation; 1998 Dec; 66(11):1477-85. PubMed ID: 9869089 [TBL] [Abstract][Full Text] [Related]
11. Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1,3Gal epitopes in alpha 1,3-galactosyltransferase-deficient mice. Ohdan H; Swenson KG; Kruger Gray HS; Yang YG; Xu Y; Thall AD; Sykes M J Immunol; 2000 Nov; 165(10):5518-29. PubMed ID: 11067905 [TBL] [Abstract][Full Text] [Related]
12. The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies. Galili U; Buehler J; Shohet SB; Macher BA J Exp Med; 1987 Mar; 165(3):693-704. PubMed ID: 2434599 [TBL] [Abstract][Full Text] [Related]
13. Characterization of natural human anti-non-gal antibodies and their effect on activation of porcine gal-deficient endothelial cells. Saethre M; Baumann BC; Fung M; Seebach JD; Mollnes TE Transplantation; 2007 Jul; 84(2):244-50. PubMed ID: 17667817 [TBL] [Abstract][Full Text] [Related]
14. Polyreactivity and antigen specificity of human xenoreactive monoclonal and serum natural antibodies. Turman MA; Casali P; Notkins AL; Bach FH; Platt JL Transplantation; 1991 Oct; 52(4):710-7. PubMed ID: 1926349 [TBL] [Abstract][Full Text] [Related]
15. T cell and T-B cell immunodeficiency disorders. Ammann AJ Pediatr Clin North Am; 1977 May; 24(2):293-311. PubMed ID: 300865 [No Abstract] [Full Text] [Related]
17. Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Gal alpha1,3Gal epitope. Liu J; Qian Y; Holgersson J Transplantation; 1997 Jun; 63(11):1673-82. PubMed ID: 9197365 [TBL] [Abstract][Full Text] [Related]
19. Blocking of human anti-pig xenoantibodies by soluble GAL alpha 1-3Gal and Gal alpha 1-2Gal disaccharides; studies in a pig kidney in vitro perfusion model. Magnusson S; Strokan V; Mölne J; Nilsson K; Rydberg L; Breimer ME Transpl Int; 2000; 13(6):402-12. PubMed ID: 11140238 [TBL] [Abstract][Full Text] [Related]
20. Human xenoreactive natural antibodies against Gal alpha (1-3) pig terminal residues are not produced by CD5+ B-lymphocytes. Pitre J; Möller E; Satake M Transplant Proc; 1996 Apr; 28(2):545. PubMed ID: 8623257 [No Abstract] [Full Text] [Related] [Next] [New Search]